Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers, including JAK2, RON, ALK, RAS and IKKe. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Merger Agreement with Eli Lilly and Company

On July 8, 2008, SGX Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation ("Lilly"), and REM Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Lilly ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub will merge with and into SGX (the "Merger"), with SGX continuing as the surviving corporation and a wholly-owned subsidiary of Lilly. As a result of the Merger, each share of SGX common stock issued and outstanding immediately prior to the effective time of the Merger (other than shares held by Lilly or Merger Sub or by stockholders of SGX who have validly exercised their appraisal rights under Delaware law) will be converted into the right to receive $3.00 in cash, without interest.

Pursuant to the terms of the Merger Agreement and as permitted under the applicable SGX equity plans, all of SGX's unvested stock options will vest prior to the effective time of the Merger. Any issued and outstanding stock options with an exercise price per share greater than or equal to $3.00 that are not exe
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Personalized ... their offering. , The aim ... match the right drug to the right patient ... appropriate treatment for a patient according to his/her ...
(Date:3/3/2015)... 2015  Johnson & Johnson Innovation LLC today announced ... (JLABS @SSF), a 30,000-square foot incubator located ... Francisco, Calif. The Johnson & Johnson Innovation, ... from across the healthcare spectrum including biotech, pharmaceutical, medical ... first resident startups have been selected, including the winners ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
(Date:3/3/2015)... March 03, 2015 GlobalStemCellsGroup.com ... faculty. Camacho Alcocer, a biomedical researcher and founding partner ... join GSCG’s team of biomedical professors who will teach ... , Criogenix SA de CV is a private company ... Institutions and Companies in Mexico (RENIECYT). , Camacho Alcocer ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... , ... therapeutics company, announces that the first clinical center in the,US, ... the phase III clinical study of Alpharadin in men with,castration-resistant ... the skeleton. , The ALSYMPCA (ALpharadin ...
... Dec. 11 Gwathmey, Inc., a pre-clinical contract ... aureus, and cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... with small businesses and the federal government. Prior ...
... ... announces the opening of a NEW 2nd North American facility in Marietta, OH. The facility ... the North American market, specifically in the area of New Product Introductions (NPI) for temperature-controlled ... Hatboro, PA ...
Cached Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... , The President of the Deutsche Forschungsgemeinschaft (DFG, ... decision by the German Federal Parliament on the Stem ... grateful for the decision taken by Parliament. We are ... towards the critical debate of the issue. The ...
... the green off the potatoes. Any child would know ... idea. The reason behind this is that they contain ... the consumer. Each night, tropical fruit-eating bats ingest ... This may become particularly problematic for pregnant or lactating ...
... researchers from around the world will present the latest ... waves at the 2008 Conference on Lasers and Electro-Optics/Quantum ... at the San Jose McEnery Convention Center in San ... for those in the lasers and electro-optics community. It ...
Cached Biology News:Why fruit-eating bats eat dirt 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 3Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 4Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 6Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 7
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Pooled Human Serum • Human serum is ... found to be negative by a test ... Antibodies to Human Immunodeficiency Virus (Anti-HIV 1/2), ... Hepatitis B Surface Antigen (HbsAg) and Non-reactive ...
... Imaging Systems offer an optional X-Ray ... researchers to conveniently capture and precisely ... and whole animals with molecular based ... molecular signals that are generated by ...
...
Biology Products: